Glycomimetics for the inhibition and modulation of lectins
Carbohydrates are essential mediators of many processes in health and disease. They
regulate self-/non-self-discrimination, are key elements of cellular communication, cancer …
regulate self-/non-self-discrimination, are key elements of cellular communication, cancer …
Biological functions and analytical strategies of sialic acids in tumor
Sialic acids, a subset of nine carbon acidic sugars, often exist as the terminal sugars of
glycans on either glycoproteins or glycolipids on the cell surface. Sialic acids play important …
glycans on either glycoproteins or glycolipids on the cell surface. Sialic acids play important …
Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses
The mammalian immune system evolved to tightly regulate the elimination of pathogenic
microbes and neoplastic transformed cells while tolerating our own healthy cells. Here, we …
microbes and neoplastic transformed cells while tolerating our own healthy cells. Here, we …
Siglec signaling in the tumor microenvironment
EJH van Houtum, C Büll, LAM Cornelissen… - Frontiers in …, 2021 - frontiersin.org
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of receptors that
recognize sialoglycans–sialic acid containing glycans that are abundantly present on cell …
recognize sialoglycans–sialic acid containing glycans that are abundantly present on cell …
Hypersialylation in cancer: modulation of inflammation and therapeutic opportunities
E Rodrigues, MS Macauley - Cancers, 2018 - mdpi.com
Cell surface glycosylation is dynamic and often changes in response to cellular
differentiation under physiological or pathophysiological conditions. Altered glycosylation on …
differentiation under physiological or pathophysiological conditions. Altered glycosylation on …
CD22: a regulator of innate and adaptive B cell responses and autoimmunity
EA Clark, NV Giltiay - Frontiers in immunology, 2018 - frontiersin.org
CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized
over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston …
over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston …
Siglec ligands
A Gonzalez-Gil, RL Schnaar - Cells, 2021 - mdpi.com
A dense and diverse array of glycans on glycoproteins and glycolipids decorate all cell
surfaces. In vertebrates, many of these carry sialic acid, in a variety of linkages and glycan …
surfaces. In vertebrates, many of these carry sialic acid, in a variety of linkages and glycan …
Targeting sialic acid–Siglec interactions to reverse immune suppression in cancer
OJ Adams, MA Stanczak, S von Gunten, H Läubli - Glycobiology, 2018 - academic.oup.com
Abstract Changes in sialic acids in cancer have been observed for many years. In particular,
the increase of sialoglycan density or hypersialylation in tumors has been described. Recent …
the increase of sialoglycan density or hypersialylation in tumors has been described. Recent …
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia
Background CD33 is genetically linked to Alzheimer's disease (AD) susceptibility through
differential expression of isoforms in microglia. The role of the human CD33 short isoform …
differential expression of isoforms in microglia. The role of the human CD33 short isoform …
CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen
S Duan, CJ Koziol-White, WF Jester… - The Journal of …, 2021 - Am Soc Clin Investig
Allergen immunotherapy for patients with allergies begins with weekly escalating doses of
allergen under medical supervision to monitor and treat IgE mast cell–mediated …
allergen under medical supervision to monitor and treat IgE mast cell–mediated …